PURE Bioscience  

(Public, OTCMKTS:PURE)   Watch this stock  
Find more results for NASDAQ:PURE
+0.02 (1.69%)
After Hours: 1.15 -0.05 (-4.17%)
Apr 17, 4:00PM EDT  
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.18 - 1.30
52 week 0.22 - 1.70
Open 1.20
Vol / Avg. 24,510.00/59,616.00
Mkt cap 32.59M
P/E     -
Div/yield     -
EPS -0.60
Shares 27.16M
Beta 0.83
Inst. own 2%

Key stats and ratios

Q1 (Jan '14) 2013
Net profit margin -6053.66% -935.49%
Operating margin -6082.93% -895.00%
EBITD margin - -789.88%
Return on average assets -349.37% -235.31%
Return on average equity -1808.41% -
Employees 13 -
CDP Score - -


EL CAJON, CA 92020
United States - Map
+1-619-5968600 (Phone)
+1-619-5968690 (Fax)

Website links


Pure Bioscience, Inc. (PURE) is focused on the discovery, development and commercialization of bioscience products. PURE�s technology platform is based on stabilized ionic silver, and its initial products contain silver dihydrogen citrate (SDC).The Company manufactures and sells SDC-based disinfecting and sanitizing products. PURE also manufactures and sells various SDC-based formulations to manufacturers for use as a raw material in the production of personal care and other products. The Company�s products include PURE Complete System, which includes PURE Hard Surface, PURE Multi-Purpose Cleaner Concentrate and PURE Floor Cleaner Concentrate; Axen 30; Axenohl, and Silverion.

Officers and directors

David Pfanzelter Independent Chairman of the Board
Age: 59
Henry R. Lambert Chief Executive Officer, Director
Age: 62
Peter C. Wulff Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Age: 54
Gary D. Cohee Director
Age: 67
William Otis Independent Director
Age: 57
David M. Theno Jr. Ph.D. Independent Director
Age: 62